Therini Bio, Inc., a South San Francisco, CA-based vascular biology company, raised 17m in seed extension round of financing.
The round was co-led by SV Health Investors’ Impact Medicine Fund, MRL Ventures, and Sanofi Ventures who join existing investors including the Dementia Discovery Fund and Dolby Family Ventures, as well as new investor, Foundation for a Better World. With the closing of the financing Dr. Christine Brennan, PhD from MRL Ventures and Dr. Jim Trenkle, PhD from Sanofi Ventures have joined the Therini board of directors.
The company intends to use the capital to accelerate the development of its lead program – a monoclonal antibody against fibrin – towards the clinic for patients with inflammatory conditions associated with vascular damage.
Co-founded by Dr. Katerina Akassoglou, PhD, and Dan Burgess, President and CEO, Therini Bio is a vascular biology company focused on discovering and developing therapeutics targeting fibrin, a new biological target for neurological and peripheral diseases. In 2020, the company announced initial seed funding of $9.35m led by the Dementia Discovery Fund, Dolby Family Ventures and Alzheimer’s Drug Discovery Foundation.
Therini, which has also received funding from the Fast Forward program of the National Multiple Sclerosis Society, is a spin-out from the Gladstone Institutes based on technology discovered in the laboratory of Dr. Katerina Akassoglou, PhD at Gladstone Institutes, UCSF, and UCSD.